Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer

Experimental and Therapeutic Medicine

Volumn 2, Issue 4, 2011, Pages 579-584

  Jellvert, Åsa ^a   Lissbrant, Ingela Franck ^a   Edgren, Maliha ^a   Övferholm, Elisabeth ^a   Braide, Karin ^a   Olvenmark, Ann Marie Ekelund ^a   Kindblom, Jon ^a   Albertsson, Per ^a   Lennernäs, Bo ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiogenesis; Castration resistant; Chemotherapy; Hormone refractory; Metronomic; Prostate cancer

Indexed keywords

CYCLOPHOSPHAMIDE; ESTRAMUSTINE; ETOPOSIDE; IDARUBICIN; KETOCONAZOLE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHOLESTASIS; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPEPSIA; FATALITY; FATIGUE; HEART FAILURE; HUMAN; HYPOTENSION; INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; NAUSEA; RASH; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

EID: 79958066552     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.272     Document Type: Article

References (28)

1. Damber JE and Aus G: Prostate cancer. Lancet 371: 1710-1721, 2008.
2. Calabro F and Sternberg CN: Current indications for chemotherapy in prostate cancer patients. Eur Urol 51: 17-26, 2007.
3. Mike S, Harrison C, Coles B, Staffurth J, Wilt TJ and Mason MD: Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev CD005247, 2006.
4. Kantoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17: 2506-2513, 1999.
5. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estra-mustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004.
6. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus pred-nisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
7. Gignac GA, Morris MJ and Hussain M: Castration resistant, taxane-naive metastatic prostate cancer: current clinical approaches and future directions. J Urol 178: S30-S35, 2007.
8. Bradley DA and Hussain M: Promising novel cytotoxic agents and combinations in metastatic prostate cancer. Cancer J 14: 15-19, 2008.
9. Hanahan D, Bergers G and Bergsland E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angio-genesis in mice. J Clin Invest 105: 1045-1047, 2000.
10. Kerbel RS and Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436, 2004.
11. Kerbel RS, Klement G, Pritchard KI and Kamen B: Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 13: 12-15, 2002.
12. Kikuchi Y, Kita T, Takano M, Kudoh K and Yamamoto K: Treatment options in the management of ovarian cancer. Expert Opin Pharmacother 6: 743-754, 2005.
13. Stempak D, Seely D and Baruchel S: Metronomic dosing of chemotherapy: applications in pediatric oncology. Cancer Invest 24: 432-443, 2006.
14. Tonini G, Schiavon G, Silletta M, Vincenzi B and Santini D: Antiangiogenic properties of metronomic chemotherapy in breast cancer. Fut Oncol 3: 183-190, 2007.
15. Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3: 2371-2376, 1997.
16. Lord R, Nair S, Schache A, et al: Low dose metronomic oral cyclophosphamide for hormone-resistant prostate cancer: a phase II study. J Urol 177: 2136-2140, 2007.
17. Millikan R, Thall PF, Lee SJ, et al: Randomized, multi center, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol 21: 878-883, 2003.
18. Tu SM, Millikan RE, Mengistu B, et al: Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 357: 336-341, 2001.
19. Logothetis CJ and Millikan R: Chemotherapy for advanced prostate cancer: 25 years later. J Clin Oncol 26: 2423-2424, 2008.
20. Berruti A, Fara E, Tucci M, et al: Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up. Urol Oncol 23: 1-7, 2005.
21. Bracarda S, Tonato M, Rosi P, et al: Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study. Cancer 88: 1438-1444, 2000.
22. Dimopoulos MA, Panopoulos C, Bamia C, et al: Oral estramus-tine and oral etoposide for hormone-refractory prostate cancer. Urology 50: 754-758, 1997.
23. Eigl BJC, Eggener SE, Baybik J, et al: Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 11: 4905-4911, 2005.
24. Glode LM, Barqawi A, Crighton F, Crawford ED and Kerbel R: Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 98: 1643-1648, 2003.
25. Fizazi K, Le Maitre A, Hudes G, et al: Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 8: 994-1000, 2007.
26. Wilkinson S and Chodak G: An evaluation of intermediate-dose ketoconazole in hormone-refractory prostate cancer. Eur Urol 45: 581-585, 2004.
27. Harris KA, Weinberg V, Bok RA, Kakefuda M and Small EJ: Low dose ketoconazole with replacement doses of hydrocorti-sone in patients with progressive androgen independent prostate cancer. J Urol 168: 542-545, 2002.
28. Haines IE and Stanley RM: Perspective on 'Chemotherapy for advanced prostate cancer: 25 years later': Is it a mirage or an oasis? J Clin Oncol 26: 4049-4051, 2008.